September 2024

– Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer1,2 – Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend

Attention assignment desks, editors and reporters VANCOUVER, BC, Sept. 19, 2024 /CNW/ – On September 23rd, 2024, Peter Routledge, Superintendent of Financial Institutions, will participate in a fireside chat at the National Insurance Conference of Canada. A media availability will follow. What

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: